Nykode Therapeutics ASA - Minutes of Annual General Meeting

Nykode Therapeutics ASA - Minutes of Annual General Meeting

Issuer

NYKODE THERAPEUTICS ASA

Oslo, Norway, May 16, 2024 - The Annual General Meeting of Nykode Therapeutics
ASA was held May 16, 2024. All proposed resolutions on the agenda were approved
in accordance with the notice for the meeting published on April 25, 2024.

Minutes of the meeting are attached hereto.

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology
specifically targets antigens to antigen presenting cells (APC), which have been
shown to induce a broad, strong and long-lasting antigen specific immune
response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer.
VB10.16 is being expanded into multiple trials for treatment of head and neck
cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen
vaccine, is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company's partnerships include Genentech within oncology and a multi-target
collaboration with Regeneron in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse
vaccine platform for the potential use in autoimmune disorders, organ transplant
rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.

Contact:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
[email protected]

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act

More information:
Access the news on Oslo Bors NewsWeb site

619044_240516 - Nykode AGM minutes.pdf